Tumor necrosis factor-alpha (TNF-α) is a central regulator of inflammation, and TNF-α
antagonists may be effective in treating inflammatory disorders in which TNF-α plays an …

Inflammatory bowel disease (IBD), most commonly referring to Crohn's disease and
ulcerative colitis, is a chronic and disabling condition with an increasing incidence in …

Background and aims Leucocyte migration to gut mucosa, mediated by integrin binding to
mucosal addressin cell adhesion molecule (MAdCAM), is a promising target for therapeutic …

The purpose of this study was to determine the effects and mechanisms of vagal nerve
stimulation (VNS) and additive effects of electroacupuncture (EA) on colonic inflammation in …

Objectives Comparative outcomes of patients with ulcerative colitis (UC) and Crohn's
disease (CD) prescribed a biologic therapy are inconclusive. The aim of this research was to …

Background Development of inflammatory bowel disease (IBD) involves the interplay of
environmental and genetic factors with the host immune system. Mechanisms contributing to …

Probiotics are viable microorganisms that are increasingly used for treatment of a variety of
diseases. Occasionally, however, probiotics may have adverse clinical effects, including …

Currently there are three TNF-α blockers available for clinical use in IBD (table 1) in
Switzerland: infliximab (Remicade®), adalimumab (Humira®) and certolizumab pegol …

Abstract Inflammatory Bowel Disease (IBD) is a chronic and frequently disabling
inflammatory disorder of the intestine. New developments in IBD therapy are primarily …

Autoimmunity and HIV : Current Opinion in Infectious Diseases Autoimmunity and HIV : Current
Opinion in Infectious Diseases Log in or Register Subscribe to journalSubscribe Get new issue …